Dong OM, Friede K, Chanfreau C, Voora D. Cost-effectiveness of CYP2C19-guided de-escalation and escalation of P2Y12 inhibitors in veterans undergoing percutaneous coronary intervention. Presented at the PMLS Virtual Series - RTP/Population Health Meeting; October 21, 2020.
Dong OM, Poonnen P. Cost-effectiveness of genomic profiling in veterans with metastatic lung adenocarcinoma. Presented at the VA Office of National Oncology Virtual Seminar; September 8, 2020. Previously presented at the Duke Center for Applied Genomics and Precision Medicine Forum.
Dong OM. Cost-effectiveness of genomic profiling in veterans with metastatic lung adenocarcinoma. Presented at the UW Genome Sciences Department Seminar; July 14, 2020. Previously presented at the Duke Center for Applied Genomics and Precision Medicine Forum.
Dong OM. Evaluation of the VA Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites. Presented at the 2020 Duke Center for Applied Genomics and Precision Medicine Virtual Forum; June 10, 2020.
Dong OM. Cost-effectiveness of genomic profiling in veterans with metastatic lung adenocarcinoma. Presented at the Duke Center for Applied Genomics and Precision Medicine Virtual Forum; May 14, 2020.
Dong OM, Roberts MC, Wu R, Reed S, Voils C, Chanfreau C, Sperber N, Gavin K, Bates J, Kelley M, Voora D. A formative evaluation plan for the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) Program. Presented at the Virtual NHGRI Research Training and Career Development Annual Meeting; March 31, 2020.